BlackRock Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BlackRock Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$44K	Buy	4,287 +588	+16%	+$5.37K	﹤0.01%	2922
2016 Q3	$37K	Buy	3,699 +252	+7%	+$2.75K	﹤0.01%	2944
2016 Q2	$39K	Sell	3,447 -84	-2%	-$1.07K	﹤0.01%	2950
2016 Q1	$48K	Sell	3,531 -14,850	-81%	-$214K	﹤0.01%	2930
2015 Q4	$348K	Buy	18,381 +5,225	+40%	+$114K	﹤0.01%	2341
2015 Q3	$247K	Buy	+13,156	New	+$224K	﹤0.01%	2459
2015 Q2	–	Sell	-23,299	Closed	-$353K	–	2970
2015 Q1	$353K	Sell	23,299 -20,269	-47%	-$283K	﹤0.01%	2308
2014 Q4	$580K	Sell	43,568 -29,887	-41%	-$386K	﹤0.01%	2178
2014 Q3	$926K	Sell	73,455 -108,516	-60%	-$1.05M	﹤0.01%	1836
2014 Q2	$1.84M	Buy	181,971 +99,771	+121%	+$964K	﹤0.01%	1504
2014 Q1	$1.11M	Buy	+82,200	New	+$1.16M	﹤0.01%	1941

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Group's CNCE Position: Q4 2016 in Review

BlackRock Group increased its Concert Pharmaceuticals, Inc. (CNCE) stake by 16% in Q4 2016, buying an estimated $5.37K and bringing the position to 4,287 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #2922.

BlackRock Group first reported a position in CNCE in Q1 2014 and has held it in 11 quarters since. The position peaked at $1.84M in Q2 2014. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

BlackRock Group held 4,287 shares of Concert Pharmaceuticals, Inc. worth $44K as of Q4 2016.
BlackRock Group bought 588 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $5.37K.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2922 holding.
BlackRock Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 11 quarters since.
BlackRock Group's Concert Pharmaceuticals, Inc. position peaked at $1.84M in Q2 2014.
89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.